The U.S. healthcare sector has just recorded its best weekly performance in six months, with the State Street Health Care Select Sector SPDR ETF (XLV) surging 3.3% over the past five trading sessions—far outpacing the broader S&P 500’s meager gain of less than 0.5% over the same period, cementing healthcare as the top-performing sector for the week.
Multiple catalysts are driving this sector-wide rally. Pharmaceutical companies continue to deliver innovative breakthroughs, while investors rotate capital from richly valued tech stocks into more attractively priced healthcare names. Persistent inflation and geopolitical uncertainties have also enhanced the appeal of defensive sectors like healthcare, which typically hold up well during economic turbulence. Long-term demographic trends further underpin the sector, as global population aging fuels growing demand for pharmaceuticals, medical devices, healthcare services, and insurance.
Against this backdrop of sector strength, pharmaceutical giant Pfizer (PFE) stands out for all the wrong reasons. The company’s shares have plummeted more than 50% from their December 2021 all-time high of $61.71, with its roughly $140 billion market capitalization largely overshadowed by competitors dominating the GLP-1 weight-loss drug craze.
Pfizer’s response to its GLP-1 deficit has been both decisive and strategic. The company paid $4.9 billion to acquire clinical-stage biotech Metsera in September 2025, gaining access to its next-generation GLP-1 candidates including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist entering Phase 3 development. In December 2025, Pfizer inked a $2.1 billion global exclusive collaboration with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, securing rights to develop, manufacture, and commercialize the oral small molecule GLP-1 agonist YP05002. Most recently, in February 2026, Pfizer established a strategic partnership with Sciwind Biosciences for exclusive commercialization rights to Ecnoglutide, a next-generation biased GLP-1 receptor agonist, in mainland China, with potential payments of up to $495 million including upfront, regulatory, and sales milestone fees.
Beyond GLP-1, Pfizer has built a robust pipeline of 96 investigational candidates as of May 5, 2026, spanning oncology, vaccines, migraine treatments, and cardiometabolic therapies. Key assets include PF’4404, a PD-1×VEGF bispecific antibody for multiple tumor types; PADCEV for bladder cancer; Nurtec ODT (rimegepant), the world’s first oral CGRP receptor antagonist for migraine already covered by China’s health insurance; and PF-07976016, a cardiometabolic drug in Phase 2 development designed for combination use with YP05002.
In the context of a recovering healthcare sector, Pfizer’s deep correction has revealed compelling contrarian value. The stock offers a substantial 6.7% dividend yield, providing investors with a solid income buffer while waiting for the company’s strategic initiatives to bear fruit. Combined with its diversified pipeline and aggressive GLP-1 expansion, Pfizer presents a balanced profile of defensiveness and growth potential. For long-term investors with a 3-5 year horizon, the stock’s current post-collapse valuation offers an attractive risk-reward ratio, positioning it as a high-quality healthcare play flying under Wall Street’s radar.
